Cabaletta Bio announced its Q3 2026 financial results and progress on its autoimmune disease therapy, rese-cel, a CAR T cell treatment. The company expects topline results from its RESET-Myositis registrational study in the second half of 2027, aiming for FDA Biologics License Application submission in early 2028, including data from juvenile dermatomyositis patients for potential priority review. Cabaletta also initiated a registrational study for systemic sclerosis with lung disease and is advancing preconditioning-free trials to optimize dosing. With $299.4 million in cash, the company is funded through Q1 2028 and will present updated clinical data at upcoming medical conferences.
Cabaletta Bio's Q3 2026 financial results and business update provide context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: Among 150 priced health-sector US stocks, 94 rose and 48 fell today. Takeda Pharmaceutical Company Limited shares rose 3.51% to USD 21.80 with a typical hold time of 18 days, contrasting with Brookdale Senior Living Inc. which fell 4.47% to USD 10.69 and a longer typical hold time of 21 days. Mesoblast Limited also gained 3.50% to USD 14.79 with a typical hold time of 16 days.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
